Agilent Technologies (NYSE:A) Issues Earnings Results

Agilent Technologies (NYSE:A) announced its earnings results on Wednesday. The medical research company reported $1.62 earnings per share for the quarter, beating the consensus estimate of $1.49 by $0.13, FiscalAI reports. Agilent Technologies had a return on equity of 24.33% and a net margin of 19.55%.The company had revenue of $1.88 billion during the quarter, compared to the consensus estimate of $1.84 billion. Agilent Technologies updated its Q4 2026 guidance to 1.710-1.740 EPS and its FY 2026 guidance to 6.180-6.210 EPS.

Agilent Technologies Stock Performance

NYSE:A traded up $0.39 during trading hours on Wednesday, reaching $155.16. 3,107,385 shares of the stock were exchanged, compared to its average volume of 2,234,282. The stock has a market capitalization of $43.82 billion, a P/E ratio of 31.16, a P/E/G ratio of 2.71 and a beta of 1.25. The firm has a 50 day simple moving average of $138.55 and a 200-day simple moving average of $126.47. The company has a quick ratio of 1.62, a current ratio of 2.10 and a debt-to-equity ratio of 0.43. Agilent Technologies has a 52 week low of $108.35 and a 52 week high of $160.51.

Wall Street Analyst Weigh In

A number of research analysts recently commented on the company. Royal Bank Of Canada began coverage on Agilent Technologies in a report on Wednesday, May 27th. They issued an “outperform” rating and a $153.00 price target for the company. Morgan Stanley upped their target price on Agilent Technologies from $160.00 to $175.00 and gave the company an “overweight” rating in a research report on Wednesday, August 12th. Piper Sandler assumed coverage on Agilent Technologies in a research note on Thursday, June 11th. They set a “neutral” rating and a $150.00 target price for the company. Bank of America raised shares of Agilent Technologies from a “neutral” rating to a “buy” rating and decreased their price target for the stock from $150.00 to $145.00 in a research report on Thursday, May 28th. Finally, Barclays increased their price objective on shares of Agilent Technologies from $145.00 to $150.00 and gave the company an “overweight” rating in a research note on Wednesday, June 24th. Two equities research analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and four have issued a Hold rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $160.24.

Hedge Funds Weigh In On Agilent Technologies

Several large investors have recently added to or reduced their stakes in A. Fiduciary Trust Co increased its stake in Agilent Technologies by 1.6% in the 3rd quarter. Fiduciary Trust Co now owns 4,931 shares of the medical research company’s stock worth $633,000 after buying an additional 77 shares during the period. IHT Wealth Management LLC boosted its position in Agilent Technologies by 4.9% in the 4th quarter. IHT Wealth Management LLC now owns 2,041 shares of the medical research company’s stock valued at $278,000 after buying an additional 96 shares during the period. UMB Bank n.a. grew its stake in Agilent Technologies by 3.0% in the 4th quarter. UMB Bank n.a. now owns 4,500 shares of the medical research company’s stock worth $612,000 after acquiring an additional 131 shares in the last quarter. Zions Bancorporation National Association UT increased its position in shares of Agilent Technologies by 17.2% during the fourth quarter. Zions Bancorporation National Association UT now owns 990 shares of the medical research company’s stock worth $135,000 after acquiring an additional 145 shares during the period. Finally, Modern Wealth Management LLC raised its stake in shares of Agilent Technologies by 5.7% during the second quarter. Modern Wealth Management LLC now owns 2,889 shares of the medical research company’s stock valued at $341,000 after acquiring an additional 157 shares in the last quarter.

About Agilent Technologies

Agilent Technologies is a global provider of scientific instrumentation, consumables, software and services for laboratories across the life sciences, diagnostics and applied chemical markets. The company’s product portfolio includes analytical instruments such as liquid and gas chromatographs, mass spectrometers, spectroscopy systems, and laboratory automation solutions, together with reagents, supplies and informatics tools that support measurement, testing and data analysis workflows. Agilent also offers instrument maintenance, qualification and laboratory services designed to help customers improve productivity and comply with regulatory requirements.

Founded as a corporate spin-off from Hewlett?Packard in 1999, Agilent has evolved through a combination of strategic restructuring and acquisitions to concentrate on life sciences, diagnostics and applied laboratories.